Lyell Immunopharma (LYEL) EBITDA (2020 - 2026)
Lyell Immunopharma recorded quarterly EBITDA of -$24.4 million in Q1 2026, up 82.65% quarter-over-quarter from -$140.7 million in Q4 2025, and up 53.36% year-over-year from -$15.9 million in Q1 2025.
Lyell Immunopharma's EBITDA history runs 7 years deep, the most recent figure standing at -$24.4 million for Q1 2026.
- In Q1 2026, EBITDA rose 53.36% year-over-year to -$24.4 million; the TTM figure through Mar 2026 stood at -$246.6 million (up 26.17% YoY), while the FY2025 annual figure was -$274.5 million, up 19.88% from the prior year.
- EBITDA came in at -$24.4 million for Q1 2026 at Lyell Immunopharma, up from -$140.7 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of -$6.0 million in Q4 2022 to a low of -$192.4 million in Q4 2024.
- A 5-year average of -$62.2 million and a median of -$51.8 million in 2023 frame the typical range for EBITDA.
- Across the five-year window, EBITDA soared 92.96% in 2022 and tumbled 764.05% in 2023, its largest moves.
- Lyell Immunopharma's EBITDA stood at -$6.0 million in 2022, then tumbled by 764.05% to -$51.8 million in 2023, then sank by 271.13% to -$192.4 million in 2024, then gained by 26.88% to -$140.7 million in 2025, then soared by 82.65% to -$24.4 million in 2026.
- According to Business Quant data, EBITDA over the past three periods registered -$24.4 million, -$140.7 million, and -$38.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -13.63 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.44 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 661.60 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 201.19 Mn |
| 10 | Lyell Immunopharma | 379.11 Mn | 379.11 Mn | - | -24.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -24.40 Mn |
| Dec 31, 2025 | -140.68 Mn |
| Sep 30, 2025 | -38.70 Mn |
| Jun 30, 2025 | -42.79 Mn |
| Mar 31, 2025 | -52.33 Mn |
| Dec 31, 2024 | -192.40 Mn |
| Sep 30, 2024 | -43.43 Mn |
| Jun 30, 2024 | -45.80 Mn |
| Mar 31, 2024 | -60.98 Mn |
| Dec 31, 2023 | -51.84 Mn |
| Sep 30, 2023 | -49.66 Mn |
| Jun 30, 2023 | -62.39 Mn |
| Mar 31, 2023 | -63.24 Mn |
| Dec 31, 2022 | -6.00 Mn |
| Sep 30, 2022 | -71.90 Mn |
| Jun 30, 2022 | -38.07 Mn |
| Mar 31, 2022 | -73.12 Mn |
| Dec 31, 2021 | -85.26 Mn |
| Sep 30, 2021 | -49.01 Mn |
| Jun 30, 2021 | -62.69 Mn |
| Mar 31, 2021 | -55.14 Mn |
| Dec 31, 2020 | -39.19 Mn |
| Sep 30, 2020 | -36.32 Mn |
| Jun 30, 2020 | -100.55 Mn |